Clinical trials
Observational Cholangiocarcinoma trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 4 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 34 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 3 |
| Weill Medical College of Cornell University | 3 |
| First Affiliated Hospital, Sun Yat-Sen University | 2 |
| Beijing Friendship Hospital | 1 |
| Beijing Tsinghua Chang Gung Hospital | 1 |
| Cambridge University Hospitals NHS Foundation Trust | 1 |
| Central Hospital, Nancy, France | 1 |
| Fondazione del Piemonte per l'Oncologia | 1 |
| Fudan University | 1 |
| Gang Chen, MD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholangiocarcinoma | 34 |
| Pancreatic Neoplasms | 12 |
| Bile Duct Neoplasms | 6 |
| Carcinoma, Hepatocellular | 5 |
| Gallbladder Neoplasms | 5 |
| Biliary Tract Neoplasms | 4 |
| Colorectal Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Liver Neoplasms | 4 |
| Stomach Neoplasms | 4 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.